Blogs and the Pharmaceutical Industry
This article presents the basics of blogging and offers several examples of how pharmaceutical companies and marketers can use blogs effectively without shooting themselves in the foot!
Pharma Marketing News Vol. 4, #11
Vol. 4, No. 11: December 2005 Welcome to the December, 2005 issue of Pharma Marketing News. Subscribe...
Merck to Shed Fat, But Not in Sales & Marketing
As reported by Gary Haber in The News Journal, Merck plans to cut 7,000 jobs (11% of its global work force) and improve manufacturing...
Sexy Reps Sell Rx Drugs
"Known for their athleticism, postage-stamp skirts and persuasive enthusiasm, cheerleaders have many qualities the drug industry looks for in its sales force," according to...
Pfizer Tries Unbranded ED DTC Ads
Despite what its own executives are saying to the FDA--i.e., unbranded DTC ads are not as effective as branded ads to drive consumers to...
AstraZeneca’s Risky Proposition
AstraZeneca stunned attendees at the recent FDA hearings -- at least those "in the know" -- with an announcement that it submitted written testimony...
Medicare Part D: Strategic Course Adjustment as Enrollment and Marketing Begin
Join us at Strategic Research Institute's Re-Visiting Your Medicare Part D Strategy: Course Adjustment as Marketing & Enrollment Begin conference November 17 - 18, 2005 in Washington, D.C. and hear how pharmaceutical companies will need to address key stakeholders when developing and implementing their own Medicare-related strategies
2nd Annual Define Appropriate and Effective Interactions with Thought Leaders and Key Opinion Leaders...
Mark your calendar for this years event presenting solutions for identifying, profiling and communicating with KOLs from early stages of clinical trials to Post-Marketing initiatives.
WSJ Cites PM Blog as “Must Read”
The Wall Street Journal, in the article "What the In-Crowd Knows", lists Pharma Marketing Blog as a blog insiders read to stay current. Here's...
Plan B FDAgate
FDA's decision to block approval of OTC status for the Plan B contraceptive is rapidly becoming the center of an FDA controversy that has...









